Harrow Health Inc (HROW) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Harrow Health Inc (HROW) has a cash flow conversion efficiency ratio of -0.317x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.99 Million) by net assets ($28.35 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Harrow Health Inc balance sheet independence to measure how much of total assets are equity-financed.
Harrow Health Inc - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Harrow Health Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check HROW cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Harrow Health Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Harrow Health Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Thai Union Group PCL
BK:TU
|
0.003x |
|
Zbit Semiconductor Inc. A
SHG:688416
|
N/A |
|
HIAG Immobilien Holding AG
SW:HIAG
|
0.015x |
|
Cpi Fim SA
WAR:OPG
|
0.001x |
|
J & J Snack Foods Corp
NASDAQ:JJSF
|
0.018x |
|
Shenzhen Hui Chuang Da Technology Co.Ltd
SHE:300909
|
0.013x |
|
Hengtong Logistic Co Ltd
SHG:603223
|
-0.077x |
|
CITIC Guoan Information Industry Co Ltd
SHE:000839
|
0.055x |
Annual Cash Flow Conversion Efficiency for Harrow Health Inc (2005–2025)
The table below shows the annual cash flow conversion efficiency of Harrow Health Inc from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Harrow Health Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $52.09 Million | $43.86 Million | 0.842x | +362.83% |
| 2024-12-31 | $69.30 Million | $-22.20 Million | -0.320x | -684.06% |
| 2023-12-31 | $70.00 Million | $3.84 Million | 0.055x | -13.50% |
| 2022-12-31 | $26.89 Million | $1.71 Million | 0.063x | -86.36% |
| 2021-12-31 | $10.93 Million | $5.08 Million | 0.465x | +1233.89% |
| 2020-12-31 | $26.83 Million | $-1.10 Million | -0.041x | -218.34% |
| 2019-12-31 | $27.42 Million | $950.00K | 0.035x | +24.83% |
| 2018-12-31 | $24.75 Million | $687.00K | 0.028x | +100.82% |
| 2017-12-31 | $2.62 Million | $-8.80 Million | -3.366x | -93.07% |
| 2016-12-31 | $6.43 Million | $-11.21 Million | -1.744x | -121.67% |
| 2015-12-31 | $-1.39 Million | $-11.14 Million | 8.045x | +1029.39% |
| 2014-12-31 | $8.15 Million | $-7.06 Million | -0.866x | -194.69% |
| 2013-12-31 | $15.11 Million | $-4.44 Million | -0.294x | -54.49% |
| 2012-12-31 | $10.00 Million | $-1.90 Million | -0.190x | -211.02% |
| 2011-12-31 | $-1.70 Million | $-291.16K | 0.171x | -92.26% |
| 2010-12-31 | $-1.04 Million | $-2.30 Million | 2.214x | +135.78% |
| 2009-12-31 | $577.21K | $-3.57 Million | -6.186x | -1016.35% |
| 2008-12-31 | $4.57 Million | $-2.53 Million | -0.554x | -9.67% |
| 2007-12-31 | $3.49 Million | $-1.76 Million | -0.505x | +82.02% |
| 2006-12-31 | $21.35K | $-60.00K | -2.810x | -145.49% |
| 2005-12-31 | $34.99K | $-40.06K | -1.145x | -- |
About Harrow Health Inc
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, in… Read more